Cheng S Quah (Cheng Quah)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors. Cancer research communications (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)